Waldenströmova makroglobulinemie
| Title in English | Waldenström macroglobulinemia |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.linkos.cz/casopis-klinicka-onkologie/2021-12-15-6-1/waldenstr-mova-makroglobulinemie/ |
| Doi | http://dx.doi.org/10.48095/ccko2021428 |
| Keywords | Waldenström macroglobulinemia; incidence; mutation; mikroRNA; prognosis |
| Description | Waldenström macroglobulinemia (WM) is a hematological malignancy; it is a monoclonal gammopathy, a disease characterized by presence of a monoclonal immunoglobulin in serum and/or urine. The median age at diagnosis is 71 years. WM is not an aggressive disease and patients with this diagnosis can live for several years. Infiltration of the bone marrow with lymphoplasmacytoid cells causes anemia, leading to various problems, mainly fatigue. Hepatomegaly, splenomegaly and lymphadenopathy can also occur. Hyperviscosity syndrome can appear and is caused by excessive production of immunoglobulin M. A mutation in MYD88 gene is detected in almost every WM patient, and in almost one third of them, a mutation in CXCR4 gene is detected. The detection of MYD88 mutation is important for a correct therapeutic strategy, since a Bruton’s tyrosine kinase inhibitor, ibrutinib, is most effective in patients with mutated MYD88 and wt CXCR4. The therapy is started when first symptoms occur. Purpose: The aim of this study is to summarize current knowledge about this disease, its diagnostics, molecular basis and treatment. |
| Related projects: |